Pharmacological inhibition of the ataxia telangiectasia and Rad3-linked protein serine/threonine kinase (ATR; generally known as FRAP-relevant protein (FRP1)) has emerged as a promising tactic for cancer procedure that exploits synthetic lethal interactions with proteins linked to DNA hurt mend, overcomes resistance to other therapies and boosts antitumour immunity. A number https://joseonr999fqb1.wikissl.com/user